Professional Documents
Culture Documents
Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-
analysis of randomized clinical trials
Yue Han, MD, Yuxin Chen, PhD, Xiaochun Liu, MD, Jingxi Zhang, MD, Huichun Su,
MD, He Wen, MD, Wei Li, MD, PhD, Xu Yao, MD, PhD
PII: S0091-6749(17)30687-5
DOI: 10.1016/j.jaci.2017.04.015
Reference: YMAI 12783
Please cite this article as: Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, Li W, Yao X, Efficacy and
safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical
trials, Journal of Allergy and Clinical Immunology (2017), doi: 10.1016/j.jaci.2017.04.015.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
4 Yue Han, MD,a,* Yuxin Chen, PhD,c,* Xiaochun Liu, MDa Jingxi Zhang, MDa
PT
5 Huichun Su, MDa He Wen, MDa Wei Li, MD, PhDb Xu Yao, MD, PhDa
RI
6
SC
7 Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union
U
b
9 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai,
AN
10 200040, P. R. China
M
c
11 Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing
13
15
C
21 liweiderma@163.com.
ACCEPTED MANUSCRIPT
22
23 Funding: This work was supported by National Natural Science Foundation of China
PT
26 Molecular Biology for Skin Diseases and STIs (Grant number 2015KF14), and the
RI
27 Milstein Medical Asian American Partnership Foundation. All the research work was
SC
28 conducted in Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and
29 STIs.
30
U
AN
31 Capsule summary: Dupilumab is a fully human monoclonal antibody that blocks
M
32 both IL-4 and IL-13. Meta-analysis of 7 randomized clinical trials showed that
35
EP
37
AC
38 Abbreviation:
39 AD atopic dermatitis
40 IL-4 interleukin-4
43 AE adverse event
PT
47 SAE severe adverse events
RI
48 RR relative risk
SC
49 BSA body surface area
53
54
D
TE
C EP
AC
ACCEPTED MANUSCRIPT
55 To the Editor:
57 interleukin-4 receptor (IL-4R) subunit, blocking both interleukin-4 (IL-4) and IL-13
58 that have been shown to play important roles in the pathogenesis of atopic dermatitis
PT
59 (AD).1-3 This study is a meta-analysis evaluating the efficacy and safety of dupilumab
RI
60 for the treatment of AD.
SC
61
62 Embase, and Web of Science databases for randomized controlled trials (RCTs)
63
U
(published between May 1, 2000 and Dec 1, 2016; English publication only) using the
AN
64 search terms dupilumab and atopic dermatitis or atopic eczema. A total of 7
M
66 IIa, one phase IIb and two phase III) including 1966 (1364/601) patients diagnosed
D
TE
68 1). In the phase I trial M4A, patients received weekly administration of 75 mg, 150
EP
69 mg, 300 mg dupilumab or placebo for 4 weeks, respectively; and in M4B, patients
C
70 received weekly doses of 150 mg or 300 mg dupilumab for 4 weeks. In the phase IIa
AC
71 trial M12, patients received 300 mg dupilumab weekly for 12 weeks, 4 while in study
73 glucocorticoids for 4 weeks. 4 In the phase IIb study, patients received dupilumab 300
74 mg once a week (300mg q1w), 300 mg every 2 weeks (300mg q2w), 200 mg every 2
75 weeks (200mg q2w), 300 mg every 4 weeks (300mg q4w), 100 mg every 4 weeks
ACCEPTED MANUSCRIPT
76 (100mg q4w), or placebo once a week (qw). 5, 6 In the two latest phase III trials,
77 SOLO1 and SOLO2, patients received 300 mg dupilumab or placebo at either weekly
7
78 or bi-weekly basis for 16 weeks. All patients were adults (18 years old), had
79 eczema area and severity index (EASI) score of >16, investigators global assessment
PT
80 (IGA) score of >3, body surface area (BSA) affected >10%, and a diagnosis of AD
RI
81 for >3 years. The characteristics of the selected studies were shown in Table I. The
SC
82 study qualities of each RCT or subgroup were evaluated using Jadad scale, and all 7
84
U
(Supplementary Table I). 4-7 All 7 trials reported adequate randomization, none was
AN
85 stopped early, and M4B, phase IIb, SOLO1 and SOLO2 trials were conducted in
M
86 multi-national study centers. All 7 studies showed a low risk of bias (Supplementary
87 Fig 2A). Begg funnel plot and Egger test showed there did not seem to have bias in
D
TE
91 Compared with the placebo control, dupilumab treatment significantly reduced the
AC
92 EASI score [standardized mean difference (SMD), -0.91; 95% CI, -0.99 to -0.83; P
93 <0.001] (Fig 1A), although three studies did not show a substantial reduction in EASI
94 score, including M4, C4, and phase IIb 100 mg q4w group. A higher percentage of
96 groups compared to placebo group [relative risk (RR)=4.64, 95% CI, 3.81-5.66,
ACCEPTED MANUSCRIPT
98 numerical-rating scale (NRS) score is -0.76 (95% CI, -0.84 to -0.68, P <0.001) (Fig
99 1C), indicating that dupilumab treatment improved the relief and the life quality of the
100 patients. The results also showed a significant decrease in the mean difference of BSA
PT
101 score within the dupilumab groups compared with the control group (SMD -0.77,
RI
102 95% CI -0.84 to -0.69, P<0.001) (Fig 1D). Furthermore, the dose-dependent efficacy
SC
103 of dupilumab was also showed. The results indicated that the most effective clinical
104 improvement was achieved by the doses of 300 mg qw and 300 mg q2w, and the
105
U
doses of 300 mg q4w and 200 mg q2w also showed significant clinical improvement,
AN
106 but were less effective; meanwhile, the dose of 100 mg q4w was almost ineffective.
M
107 Moreover, the group receiving 100mg q4w was the major source of heterogeneity in
108 this meta-analysis (Supplementary Fig 3), confirming that low dose of dupilumab was
D
TE
109 less likely to achieve satisfactory therapeutic effects as high doses of dupilumab.
110 Overall, dupilumab was well tolerated and had a favorable safety profile that was
EP
111 substantially better than most systemic agents. The commonly reported adverse events
C
112 (AE) in patients treated with dupilumab were nasopharyngitis, headache, and injection
AC
113 site reaction. We found that AE occurred at a similar rate among different trials
115 (Supplementary Fig 4A). Dupilumab treatment was associated with lower risk of
116 severe adverse events (SAE) compared to the placebo group (RR=0.44, 95% CI,
117 0.30-0.65, P<0.001) (Supplementary Fig 4B). Indeed, the frequency of SAE in pooled
ACCEPTED MANUSCRIPT
118 dupilumab group was 2.56%, while that of the pooled control group was 6.26%. The
119 major SAE in the placebo group included skin infection, inflammatory lesion,
120 impetigo and eczema herpeticum, which possibly resulted from the exacerbation of
121 AD due to the lack of effective treatment. Of note, there was a high incidence (12%)
PT
122 of herpes virus infection in the 100mg dupilumab group of the phase IIb trial 5. Finally,
RI
123 similar risks of study discontinuation between dupilumab and placebo groups were
SC
124 observed (RR=0.95, 95% CI 0.61-1.50, P=0.839) (Supplementary Fig 4C).
125 To our knowledge, this is the first systematic analysis and comparison of all
126
U
published dupilumab RCTs data for the treatment of moderate-to-severe AD. The
AN
127 trials included had high consistency in the patients enrolled, randomization and
M
128 masking, and treatment outcomes. Dupilumab was shown to be consistently more
129 effective than placebo, with a trend of a dose-dependent effect, and had a placebo-like
D
130
131 improve the effects.9 Limitations of this meta-analysis included the limited number of
EP
132 clinical trials (only 7) in this study and the risks of bias, e.g. funding from
C
133 pharmaceutical industry, might exist. Our findings suggest that dupilumab is a
AC
134 promising anti-AD medication, due to its specific action directed at the underlying
135 mechanisms of AD, resulting in its good efficacy and safety profile in severe AD
136 patients. However, further investigations still need to be performed in future studies to
137 evaluate the long-term efficacy and safety of dupilumab for the treatment of AD.
138
ACCEPTED MANUSCRIPT
PT
143 Huichun Su, MDa
RI
144 He Wen, MDa
SC
145
147
U
AN
148 From the aInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union
M
150 University, Shanghai, and cDepartment of Laboratory Medicine, Nanjing Drum Tower
D
TE
154
AC
157 Foundation of Jiangsu province (BK20151066), Open Grant of the Jiangsu provincial
158 Key Laboratory of Molecular Biology for Skin Diseases and STIs (Grant number
159 2015KF14), and the Milstein Medical Asian American Partnership Foundation. All the
ACCEPTED MANUSCRIPT
160 research work was conducted in Jiangsu Key Laboratory of Molecular Biology for
161 Skin Diseases and STIs. We thank Xiangdong Gong for help in manipulation of the
162 results.
163
PT
164 Disclosure of potential conflict of interest: The authors declare that they have no
RI
165 relevant conflicts of interest.
U SC
AN
M
D
TE
C EP
AC
ACCEPTED MANUSCRIPT
166 REFERENCES
168 Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17
169 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin
PT
170 Immunol 2013;132:361-70.
RI
171 2. Kaesler S, Volz T, Skabytska Y, Koberle M, Hein U, Chen KM, et al. Toll-like
SC
172 receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated
174 3.
U
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab
AN
175 efficacy and safety in adults with uncontrolled persistent asthma despite use of
M
179 4. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al.
EP
182 5. Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy
PT
191 7. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et
RI
192 al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl
SC
193 J Med 2016. 375:2335-2348.
195
U
Dupilumab improves the molecular signature in skin of patients with
AN
196 moderate-to-severe atopic dermatitis. J Allergy Clin Immunol
M
197 2014;134:1293-300.
198 9 Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety
D
TE
201
C
202
AC
ACCEPTED MANUSCRIPT
Figure legends:
PT
assessment (IGA) score. C, Pruritus numerical-rating scale (NRS) score. D,
RI
Body surface area (BSA) score. Horizontal lines stand for 95% Cls of the
SC
relative risk (RR) estimates. Green dots represent the standardized mean
difference (SMD). Blue dots represent the RR and diamonds represent the
U
meta-analysis summary effect estimate.
AN
M
D
TE
C EP
AC
ACCEPTED MANUSCRIPT
PT
Age of
Referenc Stud Countr Treatment Regimen(dose of AD severity of baseline EASI
Year Phase CTG dupilumab/placebo Outcome summary
e y y /control, n dupilumab) score, treatment/control
RI
group
rapid and dose-depedent
Beck et NCT0125932 75mg qw,150mg
SC
2012 M4A I U.S.A 24/6 42.61.9/37.44.3* 30.02.0/22.83.0* improvements in all clinical
al, 2014 3 qw,300mg qw for 4 weeks
index
rapid and dose-depedent
U
Beck et Multina NCT0138565 150mg qw,300mg qw for 4
2013 M4B I 27/10 42.61.9/37.44.3* 30.02.0/22.83.0* improvements in all clinical
al, 2014 tional 7 weeks
AN
index
Beck et NCT0154840 improvement in all clinical
2013 M12 IIa Europe 55/54 300mg qw for 12 weeks 33.71.4/39.41.7* 28.41.8/30.81.9*
al, 2014 4 index in dupilumab group
M
300mg dupilumab and associated with a rapid and
Beck et NCT0163904
2013 C4 IIa Europe 21/10 topic glucocorticoids qw 36.02.5/37.85.3* 23.12.7/24.14.0* sustained reduction in
D
al, 2014 0
for 4 weeks pruritus NRS
TE
300mg qw, 300mg q2w, greater EASI score
Thaci et Phase Multina NCT0185998 37.0(18.0-75.0)/37.2
2014 IIb 318/61 200mg q2w, 300mg q4w, 31.70.8/32.91.8* improvements in dupilumab
al, 2016 Ilb tional 8 (18.0-69.0)
100mg q4w for 12 weeks group
EP
Simpson 300mg qw for 16 300mg qw:30.4(21.5-40.8),
SOL Multina NCT0227774 38.0(27.5-48.0)/39.0 clinical index improvement
et 2015 III 447/224 weeks,300mg q2w for 16 300mg q2w:29.8(22.0-41.2)
C
PT
RI
U SC
AN
M
D
TE
EP
C
AC